zPremium - Thursday afternoon was our latest Healthcare Huddle webinar. We covered ongoing ideas, but focused afterwards on a slew of CNS-focused companies that are worth looking … Continue Reading
PremiumResearch - Shares of Sage Therapeutics (SAGE) fell today on news that data from STATUS — the company’s phase 3 study of SAGE-547 in SRSE – would … Continue Reading
PremiumResearch - Ionis (IONS) gained about $1.2 billion in market value this week when a phase 3 study of nusinersen, the company’s antisense drug for Spinal Muscular … Continue Reading
PremiumResearch - On Thursday evening we hosted our monthly ‘Healthcare Huddle’ webinar. We discussed: The state of the markets (why we’re cautiously bullish about equities) The state … Continue Reading
PremiumInsights - After a tumultuous and breathtaking plunge earlier this week, equities have rebounded in a big way. That’s quite constructive. The UK’s vote to leave the EU … Continue Reading
PremiumResearch - Last Thursday was PropThink’s monthly Healthcare Huddle webinar. Topics covered included: Perceived risk events: interest rates, Brexit vote, economic growth, and the U.S. presidential elections … Continue Reading
Read nowResearch - In investing and trading, understanding where expectations stand for a company or equity is half the battle. In the case of large, profitable listed companies, that’s often earnings expectations: a beat is only a beat because it topped market expectations. In the case of bio/pharma stocks, we make the same evaluations for binary events, like mid-stage study results.
Read now
